Headlands Research has announced the acquisition of AMCR Institute, which has been in operation for more than 20 years. The site’s team brings experience in metabolic, endocrine, and medical device research to the growing clinical research site network.
Led by principal investigator (PI) Timothy S. Bailey, MD, FACE, FACP, CPR, the San Diego–based clinical research site specializes in metabolic, endocrine, and other chronic conditions such as type 1 and type 2 diabetes and obesity. Bailey is a board-certified endocrinologist and is certified by the Association of Clinical Research Professionals (ACRP). He and his staff have worked with thousands of volunteers in Phase I-IV trials and have extensive experience with the evaluation of medical devices such as continuous glucose monitors (CGMs).
The acquisition of AMCR Institute, now known as Headlands Research AMCR Institute, is the most recent as the company expands its clinical research site network to support more clinical trials and provide access to investigational therapies to a diverse, representative population. Headlands Research recently launched one new clinical research site and acquired two additional established sites: Headlands Research Detroit serves multiple therapeutic areas, including Alzheimer’s disease and vaccines; Headlands Research Eastern Massachusetts specializes in neurodegenerative diseases such as Alzheimer’s disease, and Clinvest Research specializes in chronic diseases including migraine and arthritis.
Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network. (2023, July 27). Business Wire.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.